Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Ginna Laport
To assess the proportion of patients with donor neutrophil engraftment within 30 days of allogeneic transplant; assess the incidence of acute GvHD during the first 100 days after transplantation; and assess platelet engraftment, graft failure, chronic GvHD, clinical safety, and devise performance.
Age
18–50
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histopathologically-confirmed diagnosis of hematological or lymphatic malignancy, defined as one of the following:
Acute myeloid leukemia (AML) as primary refractory disease, or in relapse
Acute leukemia in first remission with poor risk factors and molecular prognosis
AML with -5,-7, t(6;9), tri8, -11
Acute lymphocytic / lymphoblastic leukemia (ALL) with Phil+ t(9;22),(q34;q11.2), and t(4:11)(q21;23)
Chronic myelogenous leukemia (CML in accelerated, second chronic phase
Myelodysplastic syndrome with high intermediate to high risk categories
Non-Hodgkin's lymphoma (NHL)
Chronic lymphocytic leukemia (CLL), Refractory \< 50 years old at time of registration Donor is related Donor is genotypically-matched and haploidentical for HLA-A, B,C and DRB1, DQ loci Donor differs for 2 or 3 HLA alleles on the unshared haplotype in the GvHD direction No HLA-matched sibling or matched unrelated donor is identified ECOG performance status not more than 2 LVEF \> 45% DLCO \> 50% corrected for hemoglobin Serum creatinine
\< 1.5 mg/dL OR
creatinine clearance \> 50 mL/min for those above serum creatinine of 1.5 mg/dL serum bilirubin \< 2.0 mg/dL ALT \< 2x ULN (unless secondary to disease) Females of childbearing potential must have a negative serum or urine beta-HCG test within 3 weeks of registration No prior cancer within 5 years with the exception of surgically-cured, non-melanoma skin cancer or in situ cancer of the cervix No prior myeloablative therapy or transplant Duly-executed informed consent
Must be seronegative donor if recipeint is seronegative.
Otherwise the donor will be selected on the ability of NK cell alloreactivity based upon HLA typing results and donors who are capable of NK cell alloreactivity will be used preferentially.
